Exact Mass: 301.0013
Exact Mass Matches: 301.0013
Found 172 metabolites which its exact mass value is equals to given mass value 301.0013,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
2-(3,5-Dichlorophenylcarbamoyl)-1,2-dimethylcyclopropane-1-carboxylic acid
2-amino-6-chloro-4-(3-sulfoanilino)-1,3,5-triazine
N-Acetylgalactosamine 4-sulphate
Also known as GalNAc4S, this molecule is a key component of dermatan, keratan and chondroitin sulfate. It is also a substrate for the enzyme N-acteylgalactosamine-4-sulphate transferase. This molecule is found in elevated concentrations in the urine of patients suffering from muchopolysaccharidosis type III, IV and VI. Levels are typically 300-400 times normal values. GalNAc4S is thought to be derived from the action of beta-N-acetylhexosaminidase on sulphated GlcNAc or GalNAc residues at the non-reducing end of keratan sulphate, dermatan sulphate or chondroitin sulphate. [HMDB] Also known as GalNAc4S, this molecule is a key component of dermatan, keratan and chondroitin sulfate. It is also a substrate for the enzyme N-acteylgalactosamine-4-sulphate transferase. This molecule is found in elevated concentrations in the urine of patients suffering from muchopolysaccharidosis type III, IV and VI. Levels are typically 300-400 times normal values. GalNAc4S is thought to be derived from the action of beta-N-acetylhexosaminidase on sulphated GlcNAc or GalNAc residues at the non-reducing end of keratan sulphate, dermatan sulphate or chondroitin sulphate.
Benoxaprofen
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D003879 - Dermatologic Agents
N-Acetylglucosamine 6-sulfate
N-acetylglucosamine 6-sulfate is a physiological intermediate during the degradation of keratan sulfate and it is usually hydrolyzed intralysosomally by N-acetylglucosamine-6-sulfate sulfatase. (PMID 3161730) [HMDB] N-acetylglucosamine 6-sulfate is a physiological intermediate during the degradation of keratan sulfate and it is usually hydrolyzed intralysosomally by N-acetylglucosamine-6-sulfate sulfatase. (PMID 3161730).
N-Acetylgalactosamine 6-sulfate
N-Acetylgalactosamine 6-sulfate is found in keratan sulfate and chondroitin 6-sulfate. PMID: 12489154. Morquio syndrome is caused by an abnormal accumulation of mucopolysaccharides - in this case, keratan sulfate - in the body. Keratan sulfate is excreted in urine. The symptoms vary from patient to patient, and may include hearing loss, cataracts, skeletal dysplasia, spinal instability, and minor respiratory issues, among others. Two forms are recognized, type A and type B. Type A is a deficiency of the enzyme N-acetylgalactosamine-6-sulfate sulfatase. (Wikipedia). N-Acetylgalactosamine 6-sulfate is found in keratan sulfate and chondroitin 6-sulfate.
2-(Acetylamino)-2-Deoxy-6-O-Sulfo-alpha-D-Glucopyranose
Azinphosmethyl oxon
Benoxaprofen
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D003879 - Dermatologic Agents
3-Hydroxycinnamoylglycine sulfate
(2-TRIFLUOROMETHYL-QUINOLIN-4-YLSULFANYL)-ACETIC ACID HYDRAZIDE
ELTENAC
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
1-(4-bromophenyl)-1,4-dihydro-3(2H)-isoquinolinone
5-benzyl-4-(4-chlorophenyl)-4H-1,2,4-triazole-3-thiol
Cisplatin; cis-Diamminedichloroplatinum(II); [PtCl2(NH3)2]; CDDP
(-)-3S-8-bromo-6-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
4-CHLORO-2-PYRIDIN-3-YL-5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDINE
ethyl 2-(2,1,3-benzothiadiazol-4-ylsulfonylamino)acetate
7-chloro-4-hydroxy-3-(4-methoxyphenyl)-1H-quinolin-2-one
5-(2-Chlorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole
5-(3-Chlorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole
5-(3-Chlorophenyl)-3-(4-nitrophenyl)-1,2,4-oxadiazole
(1S,4R)-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride
1-(4-nitrophenyl)-5-(trifluoromethyl)pyrazole-4-carboxylic acid
2-tert-Butylamino-1-(3,4,5-trichloro-2-thienyl)ethanol
2-THIAZOLECARBOXYLICACID,4-[3-(TRIFLUOROMETHYL)PHENYL]-,ETHYLESTER
N-(4-(N-(Thiazol-2-yl)sulfamoyl)phenyl)acetamide-d4
2-(4-bromophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine
2-methyl-3-(3-sulfatobutyl)benzothiazolium betaine
5-(2-Chlorophenyl)-3-(4-nitrophenyl)-1,2,4-oxadiazole
(1-(5-Bromo-3-nitropyridin-2-yl)pyrrolidin-3-yl)methanol
ETHYL 2-CHLORO-2-(2-(4-METHOXY-2-NITROPHENYL)HYDRAZONO)ACETATE
ETHYL 2-(4-(TRIFLUOROMETHYL)PHENYL)THIAZOLE-4-CARBOXYLATE
METHYL 3-AMINO-4-[(2-FURYLMETHYL)SULFONYL]THIOPHENE-2-CARBOXYLATE
4-Bromo-2-fluoropyridine-3-boronic acid pinacol ester
1-(2-CHLORO-3-PYRIDYL)-2,5-DIHYDRO-1H-PYRROLE-2,5-DIONE
4-BENZYL-5-(2-CHLORO-PHENYL)-4H-[1,2,4]TRIAZOLE-3-THIOL
Amiloride HCl dihydrate
D049990 - Membrane Transport Modulators > D026941 - Sodium Channel Blockers > D062686 - Epithelial Sodium Channel Blockers D049990 - Membrane Transport Modulators > D026941 - Sodium Channel Blockers > D062646 - Acid Sensing Ion Channel Blockers C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49186 - Potassium-Sparing Diuretic C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D004232 - Diuretics
1-(2,5-DIMETHYLPHENYL)-5-OXOPYRROLIDINE-3-CARBOXYLICACID
tert-Butyl 3-bromo-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate
4-Chloro-6-nitro-8-(trifluoromethyl)-3-quinolinecarbonitrile
4-benzyl-5-(4-chloro-phenyl)-4h-[1,2,4]triazole-3-thiol
5-methoxy-2-methyl-3-(3-sulfopropyl)benzothiazolium inner salt
4-Chloro-5-(2,4-dichlorobenzyl)-6-methyl-2-pyrimidinamine
2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
N-(4-BROMOPHENYL)-1-METHYL-1H-BENZO[D]IMIDAZOL-2-AMINE
5-(3,4-DICHLOROBENZYL)-4-PROPYL-1,2,4-TRIAZOLE-3-THIOL
1-(4-Iodo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine
3,4-Dichloro-N-(2,6-dioxotetrahydro-2H-pyran-3-yl)benzamide
(2-(4-bromophenyl)imidazo[1,2-a]pyridin-3-yl)methanamine
6-Chloro-2-(4-chlorophenyl)imidazo[1,2-α]pyridine-3-acetonitrile
Phosphoramidochloridicacid, phenyl-, 4-chlorophenyl ester (9CI)
4-bromo-9-phenyl-8-oxa-10-azabicyclo[4.4.0]deca-2,4,9,11-tetraen-7-one
(6-bromopyridin-2-yl)methoxy-tert-butyl-dimethylsilane
Benzenesulfonyl chloride, 4-[(3,5-dimethyl-4-isoxazolyl)methoxy]
methyl 2-[2-(trifluoromethyl)quinolin-4-yl thio]-acetate
4-acetamido-2-(trifluoromethyl)benzenesulfonyl chloride
ethyl 2-(2,3-dichlorophenyl)-1,3-thiazole-4-carboxylate
Ethyl 6,7-dichloro-3-hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxylate
ethyl 2-(2-amino-5,6-dichloro-4H-quinazolin-3-yl)acetate
Ethyl 2-(2,4-dichlorophenyl)thiazole-4-carboxylate
tert-Butyl1-bromo-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate
3-(4-chlorophenyl)-4-(4-methylphenyl)-1H-1,2,4-triazole-5-thione
tert-Butyl 3-bromo-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate
5-Bromo-2-fluoropyridine-3-boronic acid pinacol ester
3-bromo-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid
MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with Ki of 0.14 μM for [3H]glycine binding in vitro and in vivo.
1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-dichlorophenyl)-beta-methoxy-alpha-methyl-
2-[(4-chlorophenyl)sulfanyl]-1-methyl-1H-indole-3-carbaldehyde
3-(4-Chlorophenyl)-6-phenyl-1,4-dihydro-1,3,5-triazine-2-thione
3-(4-Chlorophenyl)-5-[(phenylthio)methyl]isoxazole
2-(3-fluoroanilino)-7-hydroxy-5-oxo-4H-thieno[3,2-b]pyridine-3-carbonitrile
2-(Acetylamino)-2-Deoxy-6-O-Sulfo-alpha-D-Glucopyranose
2-(Acetylamino)-2-deoxy-4-O-sulfo-alpha-D-galactopyranose
Methyl 2,2-dichloro-3-hydroxy-4-(methoxycarbonylamino)-5-methylhexanoate
Quercetin-7-olate
Conjugate base of quercetin arising from selective deprotonation of the 7-hydroxy group; major species at pH 7.3.
Tricetin(1-)
The conjugate base of tricetin arising from selective deprotonation of the 7-OH position; major species at pH 7.3.
2-[2,3-Dichloro-4-(2-methylidenebutanoyl)phenoxy]acetate
4-[(Z)-(4,6-dihydroxy-3-oxo-1-benzofuran-2-ylidene)methyl]-2,6-dihydroxyphenolate
3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-8-olate
2-Thiophenecarboxylic acid 2-(1,3-dioxo-2-isoindolyl)ethyl ester
(E)-N-(Benzimidazol-1-yl)-1-(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)methanimine
(E)-3-[3-[(4-chlorobenzoyl)amino]phenyl]prop-2-enoic acid
delphinidin(1-)
An organic anion obtained by selective deprotonation of the 3- and 5-hydroxy groups of delphinidin; major species at pH 7.3.
